The expression of galectin-3 and galectin-7 in epithelial dysplasia and adenocarcinoma of the stomach;Korean Sources

Korean Journal of Pathology

Volumn 42, Issue 6, 2008, Pages 365-372

  Kwak, Ji Eun ^a   Kim, Han Seong ^a   Joo, Mee ^a   Chang, Sun Hee ^a   Shim, Sang Hwa ^a   Ran, Lee Hye ^a  

^a Inje University   (South Korea)

Author keywords

Adenocarcinoma; Adenoma; Galectin 3; Galectins; Stomach

Indexed keywords

EID: 68949119681     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994; 76: 597-8.
2. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002; 1572: 232-54.
3. Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002; 1572: 263-73.
4. Perillo NL, Marcus ME, Baum LG. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 1998; 76: 402-12.
5. Hughes RC. Mac-2: a versatile galactose-binding protein mammalian tissues. Glycobiology 1994; 4: 5-12
6. Cvejic D, SavinS, Golubovic S, Paunovic I, Tatic S, Havelka M. Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology 2000; 37: 530-5.
7. Baldus SE, Zirbes TK, Weingarten M, et al. Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol 2000; 21: 258-66.
8. Schaffert C, Pour PM, Chaney WG. Localization of galectin-3 in normal and diseased pancreatic tissue. Int J Pancreatol 1998; 23: 1-9.
9. Honjo Y, Inohara H, Akahani S, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000; 6: 4635-40.
10. van den Brule FA, Waltregny D, Liu FT, Castronovo V. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000; 89: 361-7.
11. Castronovo V, Van Den Brule FA, Jackers P, et al. Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 1996; 179: 43-8.
12. Castronovo V, Liu FT, van den Brule FA. Decreased expression of galectin-3 in basal cell carcinoma of the skin. Int J Oncol 1999; 15: 67-70.
13. Saussez S, Kiss R. Galectin-7. Cell Mol Life Sci 2006; 63: 686-97.
14. Saussez S, Decaestecker C, Lorfevre F, et al. Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas. Histopathology 2008; 52: 483-93.
15. Saussez S, Cucu DR, Decaestecker C, et al. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 2006; 13: 999-1009.
16. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997; 57: 5272-6.
17. Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996; 93: 6737-42.
18. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res 1999; 59: 4148-54.
19. Fukumori T, Takenaka Y, Yoshii T, et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003; 63: 8302-11.
20. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005; 5: 29-41.
21. Ueda S, Kuwabara I, Liu FT. Suppression of tumor growth by galectin-7 gene transfer. Cancer Res 2004; 64: 5672-6.
22. He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004; 279: 4705-12.
23. Sturm A, Lensch M, Andre S, et al. Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol 2004; 173: 3825-37.
24. Kopitz J, Andre S, von Reitzenstein C, et al. Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 2003; 22: 6277-88.
25. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res 2006; 26: 1369-76.
26. Miyazaki J, Hokari R, Kato S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 2002; 9: 1307-12.
27. Sanjuan X, Fernandez PL, Castells A, et al. Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 1997; 113: 1906-15.
28. Shimamura T, Sakamoto M, Ino Y, et al. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002; 8: 2570-5.
29. van den Brule FA, Berchuck A, Bast RC, et al. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 1994; 30: 1096-9.